Related Experiment Videos
LSD and onset of schizophrenia
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|February 1, 1981
Summary
This study found no significant differences in the age of symptom onset or first admission between chronic schizophrenics who used LSD before their illness and those who did not. The findings suggest LSD use may not alter schizophrenia's early clinical presentation.
Area of Science:
- Psychiatry
- Neuroscience
- Clinical Psychology
Background:
- Schizophrenia is a complex mental disorder with multifactorial etiology.
- The potential impact of lysergic acid diethylamide (LSD) on schizophrenia onset and progression remains an area of research interest.
- Previous studies have yielded mixed results regarding the relationship between hallucinogen use and psychotic disorders.
Purpose of the Study:
- To investigate whether prior lysergic acid diethylamide (LSD) use influences the age of symptom onset in chronic schizophrenic patients.
- To compare the age at first admission for schizophrenia between patients with and without a history of LSD use.
- To elucidate the potential role of LSD as a factor in the early clinical trajectory of schizophrenia.
Main Methods:
- A matched controlled study design was employed.
- Thirty-seven chronic schizophrenic patients with a history of LSD use preceding illness onset were compared to a control group of schizophrenic patients without such history.
- Key demographic and clinical data, including age at symptom onset and age at first admission, were collected and analyzed.
Main Results:
- No statistically significant differences were observed between the LSD-exposed and non-exposed groups regarding the age at which schizophrenia symptoms first appeared.
- Similarly, the age at which patients were first admitted to the hospital for schizophrenia did not significantly differ between the two groups.
- These findings indicate that LSD use prior to illness onset did not appear to affect these specific early markers of schizophrenia.
Conclusions:
- The use of lysergic acid diethylamide (LSD) prior to the development of schizophrenia does not appear to significantly alter the age of symptom onset or the age of first hospital admission.
- This controlled study suggests that LSD may not be a significant determinant of the early clinical timing of schizophrenia.
- Further research is warranted to explore other potential long-term effects or specific symptom profiles associated with LSD use in schizophrenia.